Trials / Terminated
TerminatedNCT00557206
Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer
Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Minneapolis Veterans Affairs Medical Center · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patient receiving oxaliplatin and docetaxel will have longer progression free survival than those patients receiving standard care.
Detailed description
Oxaliplatin: 130mg/m2 given on day 1 by intravenous injection; and Docetaxel: 60mg/m2 given on day 1 by intravenous injection Cycles are repeated every 21 days until disease progression, unacceptable toxicity or subject's withdrawal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin and Docetaxel | Chemotherapy Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days. |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2007-11-12
- Last updated
- 2013-11-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00557206. Inclusion in this directory is not an endorsement.